These patients are affected more by cachexia and lower albumin levels at the time of diagnosis in comparison to patients from earlier lung cancer stages, and this impacts any potential clinical validation of NPS in NSCLC [39,40,41,42]. This evidence concerns the gene ALB and non-small cell lung carcinoma.